Highlights from Exact Sciences' 2016 JP Morgan Healthcare Conference presentation

CEO and Chairman Kevin Conroy is in San Francisco this week at the 2016 JP Morgan Healthcare Conference to share with investors a final update on Exact Sciences' progress in 2015 and the company's plans for 2016.

Exact Sciences' presentation isn't until Thursday morning, but here's a look at a few of the key slides the company will present. You can view the full presentation at the bottom of this post.


This week, Exact Sciences announced the publication of new data on Cologuard, the company's FDA -approved, non-invasive, stool-DNA colorectal cancer screening test. A study published in the peer-reviewed journal Clinical Colorectal Cancer supports that a three-year screening interval for Cologuard is cost effective.

At an average price of $600 per test, the annual, 3-year Cologuard screening costs would be $11,313 per Quality-adjusted Life Year (QALY), compared with no screening. This figure compares favorably with established strategies for cervical cancer and breast cancer screening.


To illustrate the market opportunity of Cologuard, this slide shows the result of screening just 30% of the 80 million average-risk, asymptomatic people ages 50-84 in the United States.

Screening this 30% of population regularly with Cologuard results in a $4 billion U.S market opportunity.


A recent survey conducted for Exact Sciences revealed both patients and healthcare providers' high levels of satisfaction with Cologuard.

In a sample of 300 physicians, 98% reported Cologuard met or exceeded their expectations. In a sample of 2,799, 88% of patients rated the Cologuard experience "very positive."


Using data from Exact Sciences' DeeP-C pivotal clinical study, which was published online in the New England Journal of Medicine, the company was able to calculate estimates for the amount of cancers detected by Cologuard in 2015.

Exact Sciences estimates roughly 600 patients with a positive Cologuard result in 2015 had cancer, most of which were likely (based on DeeP-C data) early-stage and therefore more treatable.


When comparing the launch of Cologuard with the launch of two blockbuster diagnostic tests, Cologuard outperforms both by a significant margin.

Cologuard's first-year revenue outpaces Cytyc's ThinPrep and Digene's HPV, both cervical cancer screening tests, by 50% and 100%, respectively.

Here's the presentation in full:

Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not for everyone and is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. For more information about Cologuard, visit www.CologuardTest.com. Rx Only.

Subscribe To The Blog